Skip to content
Logo APM
  • 登录
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
    • Māori
高级检索
  • Real-world effectiveness of pe...
  • 引用
  • 发送短信
  • 推荐此
  • 打印
  • 导出纪录
    • 导出到 RefWorks
    • 导出到 EndNoteWeb
    • 导出到 EndNote
  • 加到收藏夹
  • Permanent link
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Saved in:
书目详细资料
Main Authors: Matteo Santoni, Zin Myint, Thomas Büttner, Hideki Takeshita, Y. Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Kürönya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, ROBERT COLEMAN KEMP, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina‐Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popović, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindřich Kopecký, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino Marques Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
格式: Artigo
语言:英语
出版: 2023
在线阅读:https://doi.org/10.1007/s00262-023-03469-5
标签: 添加标签
没有标签, 成为第一个标记此记录!
  • 持有资料
  • 实物特征
  • 您的评论
  • 相似书籍
  • 职员浏览

因特网

https://doi.org/10.1007/s00262-023-03469-5

相似书籍

  • Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
    由: Matteo Santoni, et al.
    出版: (2023)
  • Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
    由: Chiara Ciccarese, et al.
    出版: (2024)
  • Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
    由: Francesco Massari, et al.
    出版: (2024)
  • Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
    由: Ondřej Fiala, et al.
    出版: (2023)
  • Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
    由: Camillo Porta, et al.
    出版: (2025)

检索选项

  • 检索历史
  • 高级检索

查找更多

  • 浏览目录
  • 按字母顺序浏览
  • 新项目

需要帮助?

  • 检索技巧
  • 咨询台
  • 常见问题

Our networks:

  • Facebook Instagram Linkedin Youtube Spotify Tiktok

Developed by

Logo de acervos digitais